Cancer phase I clinical trials: efficient dose escalation with overdose control

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Phase I cancer clinical trials aim to determine the maximum tolerated dose (MTD) of novel therapeutics.
• Traditional dose escalation methods face challenges in balancing patient safety with rapid MTD identification.
• Ethical considerations necessitate minimizing the risk of patient overdose during dose escalation.

Purpose of the Study:

• To introduce a fully adaptive dose escalation scheme for cancer Phase I trials.
• To ensure the probability of overdosing patients remains below a specified threshold.
• To optimize the speed of approaching the MTD while maintaining patient safety.

Main Methods:

• Development of a novel, fully adaptive dose escalation algorithm.
• Simulation studies comparing the proposed method against existing designs (up-and-down, stochastic approximation, continual reassessment method).
• Evaluation based on overdose control, toxicity, MTD estimation accuracy, bias, and mean squared error.

Main Results:

• The proposed adaptive scheme effectively controlled the frequency of patient overdosing.
• Compared to the continual reassessment method, it resulted in fewer overdosed patients, reduced toxicities, and comparable MTD accuracy.
• Outperformed non-parametric schemes by treating fewer patients at suboptimal dose levels and achieving smaller bias and MSE in MTD estimation.

Conclusions:

• The novel adaptive dose escalation scheme is a promising alternative for cancer Phase I clinical trials.
• It enhances patient safety by controlling overdose risk and optimizes dose selection.
• Offers improved efficiency and accuracy in MTD determination compared to current methodologies.